title: Novel and recurrent rearrangements in the CFTR gene: clinical and laboratory implications for cystic fibrosis screening.
abstract: Because standard techniques used to detect mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene do not detect single or multiple exonic rearrangements, the importance of such rearrangements may be underestimated. Using an in-house developed, single-tube, semi-quantitative fluorescent PCR (SQF PCR) assay, we analyzed 36 DNA samples submitted for extensive CFTR sequencing and identified ten samples with rearrangements. Of 36 patients with classic CF, 10 (28%) harbored various deletions in the CFTR gene, accounting for 14% of CF chromosomes. A deletion encompassing the CFTR promoter and exons 1 and 2 was detected in a sample from one proband, and in the maternal DNA as well. In another family, a deletion of the promoter and exon 1 was detected in three siblings. In both of these cases, the families were African American and the 3120+1G > A splice site mutation was also identified. These promoter deletions have not been previously described. In a third case, a deletion of exons 17a, 17b, and 18 was identified in a Caucasian female and the same mutation was detected in the paternal DNA. In the other seven cases, we identified the following deletions: exons 2 and 3 (n = 2); exons 4, 5, and 6a; exons 17a and 17b; exons 22 and 23; and exons 22, 23, and 24 (n = 2). In our series, the frequency of CFTR rearrangements in classic CF patients, when only one mutation was identified by extensive DNA sequencing, was >60% (10/16). Screening for exon deletions and duplications in the CFTR gene would be beneficial in classic CF cases, especially when only one mutation is identified by standard methodologies.
authors.affiliation: Department of Molecular Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA. feras.x.hantash@questdiagnostics.com
authors.forename: Feras M
authors.initials: FM
authors.lastname: Hantash
authors.forename: Joy B
authors.initials: JB
authors.lastname: Redman
authors.forename: Kelsey
authors.initials: K
authors.lastname: Starn
authors.forename: Ben
authors.initials: B
authors.lastname: Anderson
authors.forename: Arlene
authors.initials: A
authors.lastname: Buller
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: McGinniss
authors.forename: Franklin
authors.initials: F
authors.lastname: Quan
authors.forename: Mei
authors.initials: M
authors.lastname: Peng
authors.forename: Weimin
authors.initials: W
authors.lastname: Sun
authors.forename: Charles M
authors.initials: CM
authors.lastname: Strom
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000235:genetics*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D004252:DNA Mutational Analysis / Q000379:methods; D005091:Exons; D005192:Family Health; D005260:Female; D015321:Gene Rearrangement; D005820:Genetic Testing; D006801:Humans; D008297:Male; D009154:Mutation; D016133:Polymerase Chain Reaction / Q000379:methods; D011401:Promoter Regions, Genetic
chemical_list: C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator